Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 14/20 | 0.47 |
| ▸ | HRH1 | P35367 | 14/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17557999 | 0.93 | HRH2 (0.52) | HRH2HRH1LMNAPOLBTSHR | |
| SCHEMBL17557964 | 0.92 | HRH2 (0.51) | HRH2HRH1LMNAPOLBTSHR | |
| SCHEMBL17557975 | 0.91 | HRH2 (0.50) | HRH2HRH1 | |
| SCHEMBL17558015 | 0.91 | HRH2 (0.50) | HRH2HRH1 | |
| SCHEMBL17576888 | 0.91 | HRH2 (0.50) | HRH2HRH1 | |
| SCHEMBL17558020 | 0.91 | HRH2 (0.50) | HRH2HRH1 | |
| SCHEMBL17557974 | 0.91 | HRH2 (0.50) | HRH2HRH1 | |
| SCHEMBL17557971 | 0.91 | HRH2 (0.50) | HRH2HRH1 | |
| SCHEMBL17557993 | 0.91 | HRH2 (0.50) | HRH2HRH1 | |
| SCHEMBL17557980 | 0.91 | HRH2 (0.50) | HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512086-B2 | Compound for promoting apoptosis of cancer cells and a pharmaceutical composition containing the same and uses thereof | NATIONAL CHIAO TUNG UNIVERSITY (TW) | 2016-12-06 | — | — | US | disclosed |
| US-20160068495-A1 | COMPOUND FOR PROMOTING APOPTOSIS OF CANCER CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USES THEREOF | NATIONAL CHIAO TUNG UNIVERSITY (TW) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068495-A1 | COMPOUND FOR PROMOTING APOPTOSIS OF CANCER CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USES THEREOF | BAX, BCL2, CASP3 | HRH2 2253/4885HRH1 2319/4885LMNA 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.